10 hrs ago
Scientists publish a deep look at DNA mutations in lung cancer
The largest and most comprehensive genomic study of the most common kind of lung cancer has revealed an exhaustive library of mutations carried by tumors, providing information that could help guide scientists' efforts to devise new treatments.
Trending on the Topix Network
14 hrs ago
York residents will ride in Pan-Mass Challenge
Four residents from York will participate in the 35th annual Pan-Mass Challenge on August 2-3, the largest single athletic fundraising event in the country.
Wed Jul 02, 2014
The Washington Post
Dimon's Cancer Has 90% Cure Rate With Demanding Therapy: Health
The type of cancer Jamie Dimon has is curable in as many as 90 percent of cases with a treatment regimen that poses challenges for his demanding work schedule as chairman and chief executive officer of JPMorgan Chase & Co.
Thu Jun 26, 2014
J&J Enters Cancer Research Partnership With Dana-Farber Cancer Institute
Johnson & Johnson Innovation and Janssen Biotech recently announced a three year immuno-oncology lung cancer collaboration with the Dana-Faber Cancer Institute's Belfer Institute for Applied Cancer Science.
Tue Jun 24, 2014
Johnson & Johnson Innovation Center to fund $10 million Janssen Biotech, Dana-Farber partnership
A week after announcing partnerships with six Massachusetts-based companies, Johnson & Johnson Innovation Center said it will fund a $10 million partnership with Janssen Biotech, Inc. and Dana-Farber Cancer Institute to do work on lung cancer immunotherapy drugs.
Thu Jun 19, 2014
Scientists identify additional challenges in KRAS-driven cancers
Cancers driven by - and dependent on - the potent mutated cancer gene KRAS have an especially poor prognosis, and three decades of scientific attempts have failed to produce drugs that can attack KRAS and halt the tumors' runaway growth.
Mon Jun 16, 2014
Cellceutix Clinical Trial Of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer ... (more)
Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute
Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.
Fri Jun 13, 2014
Publicity Club of New England Presents Pan-Mass Challenge with $2,000 Check
Each year, the host of the Bell Ringer Awards selects a charity to donate proceeds from the event.
Wed Jun 11, 2014
Cape Cod Times
Hyannis store owners raffle quilt for cancer research
Islands clothing store on Main Street has a new addition to its shelves. Among its usual selection of beach garb and summer accessories hangs a large, brightly colored quilt.